ライフサイエンスコーパス: drug resistance gene

1 As as regulators of TSSG and copy gains of a drug resistance gene.

2 ribozymes that cleave a sequence in the marA drug resistance gene.

3 spleen necrosis virus (SNV) or the neomycin drug resistance gene.

4 l-time adaptive changes in expression of the drug-resistance gene.

5 autograft can be protected by transfer of a drug-resistance gene.

6 ating power to prospectively detect emerging drug resistance genes.

7 th alterations in the level of expression of drug resistance genes.

8 inant DNA products, and the presence of both drug resistance genes.

9 f cytotoxins and expresses a number of known drug resistance genes.

10 ecular inversion probes (MIPs) targeting key drug resistance genes.

11 quenced targeting 165 microhaplotypes and 15 drug resistance genes.

12 llumina MiSeq for the typing of antimalarial drug resistance genes.

13 d illustrate an in vivo approach for finding drug resistance genes.

14 ontain important antigenic and anti-malarial drug-resistance genes.

15 e strategies, including the amplification of drug-resistance genes.

16 d for selection in combination with multiple drug resistance gene 1 (MDR1) could have an enhanced eff

17 n of drug resistance proteins, such as multi-drug resistance gene-1 P-glycoprotein (MDR1) and multidr

18 ssociated with increased expression of multi-drug resistance gene ABCB1 (MDR1), whereas MRD6 (< 10(-6

19 s in two previously unreported P. falciparum drug resistance genes, an acetyl-CoA transporter (pfact)

20 n an attP-containing plasmid together with a drug resistance gene and the integrase on a separate pla

21 recent evolutionary selection both in known drug resistance genes and at new loci, and these varied

22 The availability of the two drug resistance genes and of several unique restriction

23 ds, R1 and RP4, both of which carry multiple drug resistance genes and were shown to impose an initia

24 omal rearrangements and the dissemination of drug-resistance genes and toxins(1-3).

25 Sequence types (STs), drug resistance genes, and patients' outcomes were also

26 tive-negative, but the positive and negative drug-resistance genes are replaced with differently colo

27 tures based on the permanent activation of a drug-resistance gene by the Cre recombinase.

28 ed a point mutation (homologous marker) or a drug-resistance gene cassette (non-homologous marker).

29 ited amplification and overexpression of the drug resistance gene CKS1B, which we recapitulated in hy

30 binant progeny carrying different numbers of drug resistance gene copies at the same locus, silencing

31 3' traps incorporating different drug resistance genes could be readily exchanged, simply

32 tases, can be used to efficiently excise the drug resistance gene during reverse transcription.

33 an undergo the next cycle of P1 transduction/drug resistance gene excision.

34 ey can be used to monitor viral oncogene and drug-resistance gene expression in transplant patients a

35 s is introduced into the cells to excise the drug resistance gene flanked with the lambda attL and la

36 e marrow cells through the introduction of a drug resistance gene, followed by subsequent administrat

37 However, the use of drug resistance genes for the selection of expression pl

38 strategies for in vivo cell selection using drug resistance genes have had disappointing outcomes an

39 Characterizing the molecular epidemiology of drug resistance genes helps to understand the emergence

40 It carries a drug resistance gene, hyg, and a 290-bp repeat sequence

41 Expression of the selectable drug resistance gene in retroviral vectors used for gene

42 ymorphisms (SNPs) in 4 Plasmodium falciparum drug resistance genes in 668 archived parasite-positive

43 y generated a line that excises loxP-flanked drug resistance genes in all tissues, including the germ

44 py number heterogeneity and the emergence of drug resistance genes in cancer.

45 for amplifying oncogenes in human tumors and drug resistance genes in cultured mouse cells.

46 The molecular detection of drug resistance genes in direct stool specimens had low

47 le Cre recombinase to activate expression of drug resistance genes in Escherichia coli.

48 s were highly sensitive for the detection of drug resistance genes in patients with bacterial BSIs, w

49 ce by activating its own expression and many drug resistance genes in response to antibiotics.

50 The expression of several drug-resistance genes, including MRP and p53, increases

51 depends on the chromosomal neighborhood of a drug-resistance gene inserted at different positions of

52 Often, however, the presence of this drug resistance gene interferes with the normal locus an

53 Incorporation of drug resistance genes into gene vectors has 2 important

54 tumor cell proliferation, and 4) transfer of drug resistance genes into hematopoietic stem cells to i

55 One approach to this goal is to incorporate drug resistance genes into vectors to enable in vivo sel

56 fer a methylguanine methyltransferase (MGMT) drug-resistance gene into normal bone marrow cells.

57 r for cancer gene therapy is the transfer of drug-resistance genes into bone-marrow stem cells for my

58 In this vector, the drug resistance gene is expressed in avian cells from th

59 umber of random integration sites at which a drug resistance gene is expressed.

60 Generally, a drug resistance gene is inserted with the modified gene

61 tarting with the 5" end: LTR, gag, pol, env, drug resistance gene, lac operator, ColE1, LTR.

62 lective conditions showed that the cassette (drug resistance gene-lac operator-ColE1) insert was pres

63 photropic retrovirus containing the multiple drug resistance gene leads to gene transfer not observed

64 e highly amplified and contain oncogenes and drug-resistance genes, making their presence a challenge

65 cumulation, or amplification of the multiple drug resistance gene (MDR).

66 th factor receptor (EGFR) and human multiple drug resistance gene (MDR-1).

67 The most frequently expressed drug resistance genes, MDR1 and MRP1, occur in human tum

68 odel of gene therapy the P140K mutant of the drug resistance gene methylguanine methyltransferase (MG

69 rge animals - dogs and humans - with a novel drug-resistance gene, MGMT, which is not expressed in no

70 We inserted the drug resistance genes neo and ble, conferring resistance

71 , sequence types (ST), and presence of known drug resistance genes of E. coli isolates that caused me

72 adily exchanged, simply by selecting for the drug-resistance gene of the replacement vector.

73 The PSTB2 gene is allelic to the pleiotropic drug resistance gene, PDR17, and is homologous to SEC14,

74 ivo is to include in the retroviral vector a drug resistance gene, such as the P140K mutant of the DN

75 ylobacter species clusters carrying multiple drug resistance genes that segregated with these isolate

76 ampylobacter spp. clusters carrying multiple drug resistance genes that segregated with these isolate

77 lper plasmid and restores the integrity of a drug resistance gene, thereby affording a direct selecti

78 combinase-expressing cassette and remove the drug-resistance gene, thus speeding up the generation of

79 s to breed an animal carrying a loxP-flanked drug resistance gene to an animal that expresses Cre rec

80 f normal host tissue by delivering cytotoxic drug resistance genes to marrow precursor cells and ther

81 s far greater than that observed in previous drug-resistance gene transfer studies.

82 uce transcription of multiple or pleiotropic drug resistance genes via increased expression of a zinc

83 ng a ribozyme targeted to a site in the marA drug resistance gene was constructed to contain an optim

84 trol region (rHS432A(gamma)*), but lacking a drug-resistance gene, we investigated the relationship b

85 A number of drug resistance genes, whose products include mutant for

86 ed that transfer of a vector that combines a drug-resistance gene with anti-BCR/ABL antisense (AS) se